New drug TIN816 tested for sepsis kidney damage

NCT ID NCT05507437

Completed Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called TIN816 in 20 adults in the intensive care unit who had kidney injury from sepsis. The main goal was to learn how the drug behaves in the body and whether it is safe. This was an early-stage study, so it focused on gathering information rather than proving the drug works.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY DUE TO SEPSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE KIDNEY INJURY DUE TO SEPSIS

Contacts and locations

Show contact details

Locations

Novartis Investigative Site

Genk, 3600, Belgium
Novartis Investigative Site

Ottignies, 1340, Belgium
Novartis Investigative Site

Strasbourg, 67091, France
Novartis Investigative Site

Toulouse, 31054, France
Novartis Investigative Site

Kiel, 24105, Germany
Novartis Investigative Site

Debrecen, 4032, Hungary
Novartis Investigative Site

Valencia, 46026, Spain